Inactive Instrument

News US Rare Earth Minerals Inc Other OTC

Equities

US9034101082

End-of-day quote Other OTC Other stock markets
- ^USD	-

Apr. 19	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 22	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist	Mar. 06	AQ
Bioxytran, Inc. Announces Preprint of Shingles Case Study Showing Clearance Using A Topical Galectin-3 Antagonist	Mar. 06	CI
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19	Feb. 21	AQ
Bioxytran, Inc.'S Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for Covid-19	Feb. 21	CI
Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Bioxytran Gets Broad Patent Coverage on 60+ Viruses	23-10-24	AQ
Bioxytran Interview at the Emerging Growth Conference	23-10-04	AQ
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M	23-09-14	AQ
Bioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patients	23-09-07	AQ
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials	23-08-31	AQ
Bioxytran, Inc. Receives Clearance of its Investigational New Drug Application from U.S. Food and Drug Administration to Initiate Clinical Trials of ProLectin-M	23-08-24	CI
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials	23-08-24	AQ
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients	23-08-08	AQ
Bioxytran, Inc. Initiates A Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID 19 Patients	23-08-08	CI
Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31	CI
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board	23-07-31	AQ
China metals export curbs lift shares in US producer MP Materials	23-07-05	RE
China rare earth curbs lift shares in U.S. producer MP Materials	23-07-05	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News US Rare Earth Minerals Inc Other OTC

Equities

US9034101082

Summary

Filters